Hunan Hansen Pharmaceutical Co., Ltd. (002412)

Hunan Hansen Pharmaceutical Co., Ltd. (002412)

Hunan Hansen Pharmaceutical Co., Ltd. (stock code 002412) was listed on the small and medium-sized board of Shenzhen Stock Exchange in may2010. The first local enterprise listed in Yiyang City was formerly Hunan Yiyang pharmaceutical factory. The company is located in Longling industrial concentration zone, Heshan District, Yiyang City, covering an area of 165116 square meters, with a total construction area of 79695 square meters, and 1300 employees, registered capital of 503.2 million yuan and total assets of nearly 2 billion yuan. It has the jurisdiction of Hanson health industry (Hunan) Co., Ltd., Hunan Hanson Pharmaceutical Research Co., Ltd., Yunnan yongzitang Pharmaceutical Co., Ltd. The annual sales revenue is nearly RMB 1billion, and the annual tax payment is nearly 200 million yuan.

The company mainly produces traditional Chinese medicine preparations, supplemented by chemical drugs, and 155 existing drug approval numbers, of which 92 specifications of 55 varieties are listed in the national basic medical insurance, industrial injury insurance and maternity insurance drugs catalogue, 34 varieties 73 specifications are listed in OTC directory, 38 varieties and 57 specifications are listed in the national basic drug catalogue. The products mainly involve digestive system medicine, cardiovascular system medicine, respiratory system medicine, injury medicine, diagnosis medicine. The leading products are sipuotang oral liquid, ginkgo leaf capsule, Koizumi capsule, etc.

The company has more than 20 invention patents, and Hanson is a famous trademark in China. The research project of simotong oral liquid has been selected into the national "973" plan, and has Hunan enterprise technology center, Hunan digestive tract Pharmaceutical Engineering Technology Research Center, Hunan University "innovative drug research and development" production, learning and research cooperation demonstration base.

The future development plan is: adhere to the main business of Chinese patent medicine - continue to be the market of dahansen simuo Decoction oral liquid, and make the products such as Koizumi capsule into star products; Based on Tianma Xingnao capsule, we will build the first brand of modern plateau botanical medicine. Extend the large health industry - a health industrial park with an area of over 2000 mu, and the industry extends to the upstream and downstream fields such as the construction of Chinese medicine base and medical care. Integrate financial industry - establish Sanxiang Bank jointly with Sany group. Based on the industry extension and integration of traditional Chinese medicine industry, we strive to become the top 50 pharmaceutical industry in China and become the leading comprehensive pharmaceutical enterprise in China.

>>server parts deals for server parts picker Tungsten Rings for Men and Women boxingcsk